ID   Rh28
AC   CVCL_8752
AS   CVCL_5919
SY   RH28; Rh-28; Rh 28; SJRH-28; SJRH 28; SJRH28
DR   BTO; BTO:0005384
DR   cancercelllines; CVCL_8752
DR   Cell_Model_Passport; SIDM01333
DR   Cosmic; 687955
DR   Cosmic; 1097748
DR   Cosmic; 1104561
DR   Cosmic; 1108740
DR   Cosmic; 1718360
DR   Cosmic; 2356025
DR   Cosmic; 2820091
DR   DepMap; ACH-001740
DR   GEO; GSM1676332
DR   GEO; GSM1701664
DR   IARC_TP53; 24980
DR   PRIDE; PXD000589
DR   PRIDE; PXD039480
DR   Wikidata; Q54950336
RX   CelloPub=CLPUB00569;
RX   PubMed=3607778;
RX   PubMed=7536457;
RX   PubMed=8275086;
RX   PubMed=8383879;
RX   PubMed=9802058;
RX   PubMed=9823299;
RX   PubMed=11051265;
RX   PubMed=21948088;
RX   PubMed=22142829;
RX   PubMed=23665679;
RX   PubMed=23882450;
RX   PubMed=25894527;
RX   PubMed=26351324;
RX   PubMed=28196595;
RX   PubMed=36768928;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Characteristics: Established from a immuno-deficient mice xenograft (HxRh28).
CC   Doubling time: 58.8 hours (PubMed=3607778).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Heterozygous (DepMap=ACH-001740).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
CC   Omics: Deep exome analysis.
CC   Omics: Cell surface proteome.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Axillary lymph node; UBERON=UBERON_0001097.
ST   Source(s): COG; PubMed=21948088
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 12,13
ST   D16S539: 11,12
ST   D18S51: 15,20
ST   D19S433: 14,15.2
ST   D21S11: 31.2,32.2
ST   D2S1338: 18,25
ST   D3S1358: 14,17
ST   D5S818: 7,11
ST   D7S820: 10,11
ST   D8S1179: 12,13
ST   FGA: 22
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L415 ! Rh3
SX   Male
AG   17Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 28
//
RX   CelloPub=CLPUB00569;
RA   Dickman P.S., Tsokos M.G., Triche T.J.;
RT   "Biology of rhabdomyosarcoma: cell culture, xenografts, and animal
RT   models.";
RL   (In) Rhabdomyosarcoma and related tumors in children and adolescents; Maurer H.M., Ruymann F.B., Pochedly C.E. (eds.); pp.49-88; CRC Press; Boca Raton (1991).
//
RX   PubMed=3607778;
RA   Hazelton B.J., Houghton J.A., Parham D.M., Douglass E.C.,
RA   Torrance P.M., Holt H., Houghton P.J.;
RT   "Characterization of cell lines derived from xenografts of childhood
RT   rhabdomyosarcoma.";
RL   Cancer Res. 47:4501-4507(1987).
//
RX   PubMed=7536457; DOI=10.1002/gcc.2870120305;
RA   Biegel J.A., Nycum L.M., Valentine V.A., Barr F.G., Shapiro D.N.;
RT   "Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar
RT   rhabdomyosarcoma by fluorescence in situ hybridization.";
RL   Genes Chromosomes Cancer 12:186-192(1995).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=8383879; DOI=10.1126/science.8383879;
RA   Tapscott S.J., Thayer M.J., Weintraub H.M.;
RT   "Deficiency in rhabdomyosarcomas of a factor required for MyoD
RT   activity and myogenesis.";
RL   Science 259:1450-1453(1993).
//
RX   PubMed=9802058;
RA   McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A.,
RA   Harris L.C.;
RT   "Bax is an important determinant of chemosensitivity in pediatric
RT   tumor cell lines independent of Bcl-2 expression and p53 status.";
RL   Oncol. Res. 10:235-244(1998).
//
RX   PubMed=9823299;
RA   Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T.,
RA   Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.;
RT   "Gene expression profiling of alveolar rhabdomyosarcoma with cDNA
RT   microarrays.";
RL   Cancer Res. 58:5009-5013(1998).
//
RX   PubMed=11051265;
RA   Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.;
RT   "Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced
RT   apoptosis and highly sensitive to TRAIL-induced apoptosis.";
RL   Clin. Cancer Res. 6:4119-4127(2000).
//
RX   PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004;
RA   Belyea B.C., Naini S., Bentley R.C., Linardic C.M.;
RT   "Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma
RT   tumorigenesis.";
RL   Clin. Cancer Res. 17:7324-7336(2011).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=36768928; DOI=10.3390/ijms24032601;
RA   Timpanaro A., Piccand C., Uldry A.-C., Bode P.-K., Dzhumashev D.,
RA   Sala R., Heller M., Rossler J., Bernasconi M.;
RT   "Surfaceome profiling of cell lines and patient-derived xenografts
RT   confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as
RT   surface targets for rhabdomyosarcoma.";
RL   Int. J. Mol. Sci. 24:2601.1-2601.28(2023).
//